impact factor, citescore
logo
 

Review

 

Systemic lupus erythematosus: one year in review 2024


1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

 

  1. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  2. Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Ferrara, Italy.
  3. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  4. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  5. Rheumatology Unit, Department of Clinical and Molecular Sciences, Carlo Urbani Hospital, Polytechnic University of Marche, Jesi, Ancona, Italy.
  6. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  7. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  8. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, and Department of Medical Biotechnologies, University of Siena, Italy.
  9. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, and Department of Medical Biotechnologies, University of Siena, Italy.
  10. Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Ferrara, Italy.
  11. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. chiaratani78@gmail.com

CER17631
2024 Vol.42, N°3
PI 0583, PF 0592
Review

Free to view
(click on article PDF icon to read the article)

PMID: 38545801 [PubMed]

Received: 03/03/2024
Accepted : 20/03/2024
In Press: 27/03/2024
Published: 27/03/2024

Abstract

Systemic lupus erythematosus (SLE) is classically regarded as the landmark of systemic autoimmune diseases, characterised by protean, multi-systemic manifestations and a highly variable clinical course. Over the last years, both clinical and translational clinical research efforts led to significant steps forward in management and treatment of SLE. However, numerous aspects of SLE, from pathogenesis to treatment, still remain challenging, and several unmet needs persist for both patients and physicians. Following the previous annual reviews of this series, herewith, we aim to report the most relevant new updates on SLE, issued in 2023. In particular, we focused on biomarkers, clinical aspects and outcomes, comorbidities, as well as new treatment targets and real-world evidence.

DOI: https://doi.org/10.55563/clinexprheumatol/mnvmvo

Rheumatology Article